Drug Discovery World

JUNE 12, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene therapies for the benefit of patients worldwide. First, the importance of cell collections.

Gene Therapy 52

Gene Therapy Manufacturing Gene Development 52

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The 2024 Drugs to Watch, are: 1.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections. MUNICH, Germany, Jan.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond , Ph.D. . VANCOUVER, BC , Jan. ” Chris Bond , Ph.D.,

Engineer 52

Engineer Gene Editing Genome Genomics 52

Drug Discovery World

JULY 3, 2023

In the Modulating Tumour Microenvironment programme, experts took a deeper look at the results we are seeing from emerging immunotherapies such as immune checkpoint blockade and chimeric antigen receptor T cells (CAR Ts), and also discussed advances in our understanding of and strategies to modulate the tumour microenvironment.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. There is significant unmet medical need for a sustained therapy to treat eye diseases. MUNICH, Germany, Jan.

Gene Therapy 52

Gene Therapy Gene Research Protein 52

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. To what do you attribute your success?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Camargo

OCTOBER 15, 2020

Often, to gain clinical trial design insights, a sponsor reviews the physician package inserts from approved New Drug Applications (NDAs) and Biologics License Applications (BLAs) with similar indications or in the same therapeutic area. The efficacy outcome should not be influenced by medical management and alternative therapies.

Production 190

Production Trials Development Clinical Trials 190

Drug Discovery World

FEBRUARY 13, 2023

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. which genes are upregulated, and which ones are downregulated – which is very useful when studying different disease states.

RNA 52

RNA Drugs Gene Expression Gene 52

pharmaphorum

APRIL 29, 2021

The Blood-Brain Barrier Summit is the industry’s first meeting dedicated to targeting the blood-brain barrier in order to develop clinically efficacious therapeutics for CNS indications. The Blood-Brain Barrier Summit will take place online from June 28-30, 2021. An Industry-focused Meeting. A Meeting Point for the Field’s Experts.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

Delveinsight

JANUARY 19, 2021

Fujifilm Increases Legroom In Cell And Gene Therapy, Plans For New Manufacturing Facility. CABIM plans to help make new therapeutics, medicines, and technologies accessible to patients and strengthen Greater Boston’s position as the world’s life science capital.

Manufacturing 40

Manufacturing Gene Therapy Life Science FDA Approval 40

Roots Analysis

OCTOBER 24, 2023

Moreover, it is worth mentioning that various advantages of disposable bioreactors have prompted biomanufacturers to adopt single-use systems in small scale R&D activities in the field of recombinant protein therapeutics, monoclonal antibody-based products, and cell-based products.

Manufacturing 40

Manufacturing Contamination Marketing Production 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Protein Antibody 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

NOVEMBER 14, 2022

Just taking a small snapshot of the current sector shines a light on the depth of development taking place. By Lu Rahman . There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. billion in 2021 to $33.2 during the forecast period of 2021-2026.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

SEPTEMBER 15, 2020

Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3. 27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. BNT162 mRNA-based Vaccine Program.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52